MX2019007890A - Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. - Google Patents

Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.

Info

Publication number
MX2019007890A
MX2019007890A MX2019007890A MX2019007890A MX2019007890A MX 2019007890 A MX2019007890 A MX 2019007890A MX 2019007890 A MX2019007890 A MX 2019007890A MX 2019007890 A MX2019007890 A MX 2019007890A MX 2019007890 A MX2019007890 A MX 2019007890A
Authority
MX
Mexico
Prior art keywords
stem
pyrrole
renewal
methods
dione compounds
Prior art date
Application number
MX2019007890A
Other languages
English (en)
Inventor
Tait Bradley
Loose Christopher
Manchanda Rajesh
Mclean Will
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of MX2019007890A publication Critical patent/MX2019007890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de 1H-pirrol-2,5-diona y a métodos para usar os mismos para inducir la auto-renovación de células madre/progenitoras de soporte, incluida la inducción de la proliferación de células madre/progenitoras mientras se mantiene, en las células hijas, la capacidad de diferenciarse en células tisulares.
MX2019007890A 2016-12-30 2017-12-21 Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. MX2019007890A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662441060P 2016-12-30 2016-12-30
US201762484282P 2017-04-11 2017-04-11
PCT/US2017/067885 WO2018125746A1 (en) 2016-12-30 2017-12-21 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells

Publications (1)

Publication Number Publication Date
MX2019007890A true MX2019007890A (es) 2020-01-20

Family

ID=60972503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007890A MX2019007890A (es) 2016-12-30 2017-12-21 Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.

Country Status (12)

Country Link
US (2) US11066419B2 (es)
EP (1) EP3562827A1 (es)
JP (1) JP7109446B2 (es)
KR (1) KR20190104359A (es)
CN (1) CN110392686A (es)
AU (1) AU2017386417B2 (es)
BR (1) BR112019013388A2 (es)
CA (1) CA3048220A1 (es)
IL (1) IL267601A (es)
MX (1) MX2019007890A (es)
SG (1) SG10201910821XA (es)
WO (1) WO2018125746A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3837350A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating pi3k
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
JP2022523158A (ja) 2019-02-08 2022-04-21 フリークエンシー セラピューティクス インコーポレイテッド エピジェネティック標的を阻害することにより有毛細胞を生成するための組成物及び方法
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
AU2020219373A1 (en) 2019-02-08 2021-08-12 Frequency Therapeutics, Inc. TAZ activators and Wnt agonists for treating ear disorders
EP3952854A1 (en) 2019-04-08 2022-02-16 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
CN111205231B (zh) * 2020-02-24 2021-12-17 浙江大学 作为ankrd22抑制剂的先导化合物及其应用
WO2022241117A2 (en) * 2021-05-12 2022-11-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered antimicrobial peptides and usage thereof

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5561163A (en) 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5837681A (en) 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
JP2001275095A (ja) 2000-03-27 2001-10-05 Sony Corp 通信方法、通信サービス装置、通信端末装置および通信システム
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
JP4808895B2 (ja) 2000-03-30 2011-11-02 キュリス，インコーポレイテッド 細胞増殖の小型有機分子レギュレーター
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US20050070578A1 (en) 2000-03-30 2005-03-31 Baxter Anthony David Small organic molecule regulators of cell proliferation
EP1267616B1 (en) 2000-03-31 2007-08-08 The General Hospital Corporation Methods of increasing hair growth by wnt polypeptide
CN100358867C (zh) 2000-05-11 2008-01-02 科学研究高等机关 糖原合酶激酶gsk-3的杂环抑制剂
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
EP1362047B1 (en) 2000-12-08 2006-05-17 Ortho-McNeil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
US20050227936A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
AU2003215325B8 (en) * 2002-03-05 2008-10-09 Eli Lilly And Company Purine derivatives as kinase inhibitors
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
WO2003097639A1 (en) 2002-05-15 2003-11-27 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
SI1532145T1 (sl) 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
AP2005003260A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel triazole compounds as transforming growth factor (TGF) inhibitors.
AU2003263431A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
JP4664205B2 (ja) 2002-10-15 2011-04-06 アイアールエム エルエルシー 骨形成を誘導する組成物および方法
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004058720A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor
WO2004067530A1 (en) 2003-01-27 2004-08-12 Pfizer Products Inc. Isothiazole derivatives
EP1603908B1 (en) 2003-03-12 2008-06-11 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
WO2004087056A2 (en) 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
WO2004112710A2 (en) 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
GB0316756D0 (en) 2003-07-17 2003-08-20 Bp Chem Int Ltd Process
WO2005009287A2 (en) 2003-07-21 2005-02-03 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
NZ545544A (en) 2003-08-13 2009-04-30 Univ Illinois Silencing of TGF-beta receptor type II expression by sirna
JP4688680B2 (ja) 2003-10-28 2011-05-25 独立行政法人理化学研究所 ＴＧＦ−β情報伝達経路阻害剤
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
US20050245508A1 (en) 2003-12-24 2005-11-03 Scios, Inc. Treatment of malignant gliomas with TGF-beta inhibitors
US7368445B2 (en) 2004-03-01 2008-05-06 Eli Lilly And Company Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2007176795A (ja) 2004-08-18 2007-07-12 Univ Nihon ＴＧＦ−β遺伝子発現抑制剤
US8771754B2 (en) 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
DK1846406T5 (da) * 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
WO2006105063A1 (en) 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
EP2949328B1 (en) 2005-03-29 2022-07-20 The Trustees of The University of Pennsylvania Minoxidil for generating new hair follicles and treating baldness
CN103356706B (zh) 2005-03-31 2016-01-20 斯丹姆涅恩有限公司 促进无疤愈合或改善皮肤外观的美容制剂
ES2330789T3 (es) 2005-06-30 2009-12-15 Janssen Pharmaceutica Nv Anilino-piridinotriazinas ciclicas como inhibidores de gsk-3.
EP1910370B1 (en) 2005-07-22 2015-04-22 Eli Lilly And Company A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US20090263410A1 (en) 2005-10-24 2009-10-22 Proyecto De Biomedicina Cima, S.L. Use of tgf-b1 inhibitor peptides in the preparation of an immune response modulating agent
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
ES2419232T3 (es) 2006-06-27 2013-08-20 Shiseido Company, Limited Agregado de células que comprende diversas clases de células derivadas del soma con capacidad para formar una estructura de tipo órgano primitivo
TWM303325U (en) 2006-07-13 2006-12-21 Everlight Electronics Co Ltd Light emitting diode package
AU2007287319A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Pyrimidone compounds as GSK-3 inhibitors
JP5138253B2 (ja) 2006-09-05 2013-02-06 東京エレクトロン株式会社 アニール装置
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008057497A2 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057469A1 (en) 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2008077138A1 (en) 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP2146724A2 (en) 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
DE102007021348A1 (de) 2007-05-06 2008-11-20 Universitätsklinikum Hamburg-Eppendorf (UKE) Verfahren zur Simulation der Haptik einer Interaktion eines geführten Gegenstandes mit einem virtuellen dreidimensionalen Objekt
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
DE102007032977A1 (de) 2007-07-16 2009-01-22 Universität Tübingen Neue Cyclische Amide, Verfahren zu deren Herstellung und ihre Verwendung
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2231164A1 (en) 2007-12-03 2010-09-29 The Regents of the University of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8822410B2 (en) 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120059021A1 (en) 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US9045737B2 (en) 2008-12-13 2015-06-02 Dnamicroarray, Inc. Artificial three-dimensional microenvironment niche culture
WO2010075551A1 (en) 2008-12-24 2010-07-01 Massachusetts Institute Of Technology Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP2406266B1 (en) 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
JP2012530492A (ja) 2009-06-17 2012-12-06 アデランス リサーチ インスティテュート，インコーポレイティド 真皮細胞の発毛促進能を増大させるための方法および組成物
WO2011019957A1 (en) 2009-08-12 2011-02-17 University Of Southern California Method for formation of induced pluripotent stem cells
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
SI2494039T1 (sl) 2009-10-31 2020-03-31 Genesis Technologies Limited Postopek reprogramiranja celic in njihova uporaba
US20110135756A1 (en) 2009-12-08 2011-06-09 University Of Washington Compositions and methods for protecting sensory hair cells
JP5627705B2 (ja) 2009-12-28 2014-11-19 アウディオキュア ファーマ ゲーエムベーハー 聴力損傷および目まいの治療用のβ−カルボリン
MX2012008328A (es) 2010-01-19 2012-08-08 Astrazeneca Ab Derivados de pirazina.
WO2011109711A1 (en) 2010-03-05 2011-09-09 Duke University Glucocorticoid drugs as smoothened agonists
US9394522B2 (en) 2010-03-22 2016-07-19 Takara Bio Europe Ab Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of Wnt-signalling pathway
EP2569430B1 (en) 2010-05-12 2018-10-17 The Trustees of Columbia University in the City of New York Methods for producing enteroendocrine cells that make and secrete insulin
HUE054810T2 (hu) 2010-08-18 2021-09-28 Biosplice Therapeutics Inc Diketonok és hidroxiketonok mint katenin-jelzõút aktivátorok
WO2012024584A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
JP5875007B2 (ja) 2010-11-02 2016-03-02 国立大学法人 熊本大学 腸細胞の製造方法
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
WO2012103012A1 (en) 2011-01-24 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for generating inner ear cells in vitro
WO2012115575A1 (en) 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
CN102276615B (zh) * 2011-08-26 2013-10-23 四川大学 一种制备甲酰阿地咪的方法
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
SI2838888T1 (sl) 2012-02-24 2017-09-29 Asd Therapeutics Partners Llc Tiadiazolidindioni kot gsk-3 inhibitorji
US9370510B2 (en) * 2012-02-24 2016-06-21 Fate Therapeutics, Inc. Small molecule compounds to treat hearing loss
US9457009B2 (en) 2012-05-31 2016-10-04 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for preventing and treating auditory dysfunctions
WO2013192225A1 (en) * 2012-06-18 2013-12-27 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
AU2013312305B2 (en) 2012-09-07 2018-06-28 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014050779A1 (ja) 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
WO2014083132A1 (en) 2012-11-29 2014-06-05 Cellectis Sa Maturation of hepatocyte-like cells derived from human pluripotent stem cells
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
HUE049377T2 (hu) 2013-03-14 2020-09-28 Brigham & Womens Hospital Inc Készítmények és eljárások epiteliális õssejtek expanziójára és tenyésztésére
CA2911205A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
AU2014302458A1 (en) * 2013-06-26 2015-12-24 Proteostasis Therapeutics, Inc. Methods of modulating CFTR activity
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
WO2015175783A1 (en) 2014-05-15 2015-11-19 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
AU2015305373B2 (en) 2014-08-20 2020-12-10 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016054406A1 (en) 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US9913848B2 (en) 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
US10016507B2 (en) 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
WO2018125746A1 (en) * 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
EP3609998A1 (en) 2017-04-11 2020-02-19 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
US20200316089A1 (en) 2017-12-21 2020-10-08 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
WO2019126686A1 (en) 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same

Also Published As

Publication number Publication date
KR20190104359A (ko) 2019-09-09
AU2017386417B2 (en) 2022-07-14
EP3562827A1 (en) 2019-11-06
CA3048220A1 (en) 2018-07-05
US20190352313A1 (en) 2019-11-21
BR112019013388A2 (pt) 2020-03-03
US20210300948A1 (en) 2021-09-30
SG10201910821XA (en) 2020-01-30
IL267601A (en) 2019-08-29
WO2018125746A1 (en) 2018-07-05
US11066419B2 (en) 2021-07-20
JP7109446B2 (ja) 2022-07-29
AU2017386417A1 (en) 2019-07-11
JP2020503340A (ja) 2020-01-30
CN110392686A (zh) 2019-10-29

Similar Documents

Publication Publication Date Title
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
PH12019501227A1 (en) Synthetic immune receptors and methods of use thereof
NZ765695A (en) Immune cell organoid co-cultures
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
SG10201810723VA (en) Improved t cell compositions
MY181994A (en) Immuno-modulatory progenitor (imp) cell
IL272541A (en) Purified mesenchymal stem cell exosomes and their uses
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
MY193806A (en) Affinity-oligonucleotide conjugates and uses thereof
WO2014124087A8 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
HK1202581A1 (en) Mesenchymal stem cells conditioned medium and methods of generating and using the same
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2016016756A (es) Terapia con células madre en patologías endometriales.
WO2017151909A3 (en) Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition
MX2017004288A (es) Medio de induccion y metodos para el cultivo de y terapias con celulas madre.
SG11202107732XA (en) Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
IL268194B (en) Environment and methods to increase survival and proliferation of embryo cells
PH12015501282B1 (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
ZA202000574B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
IL258267B (en) Methods for multiplying mesenchymal stem cells for use in transplantation
HK1254739A1 (zh) 從年長細胞群中富集和擴增高潛能人間充質幹細胞
MX2016014628A (es) Metodo para expandir las celulas madre adultas de sangre entera.
MY161163A (en) Culture medium for human mesenchymal stem cells